{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:24:14Z","timestamp":1791336254269,"version":"4.3.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6-7","license":[{"start":{"date-parts":[[2007,5,11]],"date-time":"2007-05-11T00:00:00Z","timestamp":1178841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with atrial fibrillation (AF) who also have heart failure have a worse outcome but the diagnosis of heart failure is often missed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To compare the effects of warfarin and ximelagatran on morbidity and mortality in patients with AF with and without markers of heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Data for 7329 patients from two randomised controlled trials were merged. Treatment with loop diuretics or the presence of left ventricular dysfunction, were used as markers of possible heart failure. The 3555 (49%) patients with markers of heart failure had higher composite event rates on warfarin (10.81% per year [py] [95% CI 9.59 to 12.13]) compared to the 3774 (51%) patients without markers of heart failure (4.18% py [95% CI 3.44 to 5.01]). The composite event rate was lower on ximelagatran overall (6.18% py [95% CI 5.51 to 6.89] versus 7.34% py [95% CI 6.63 to 8.10] on warfarin; P=0.0219 for the difference) with similar effects in each trial and in patients with and without markers of heart failure, mainly due to fewer heart-failure events (hazard ratio 0.69 [95% CI 0.54 to 0.87]; P&amp;lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with markers of heart failure, even if the diagnosis is not well established, are at increased risk of thromboembolic events and might be targeted for more effective antithrombotic therapy. This might include patients in sinus rhythm as well as AF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ejheart.2007.01.013","type":"journal-article","created":{"date-parts":[[2007,4,10]],"date-time":"2007-04-10T15:06:17Z","timestamp":1176217577000},"page":"730-739","source":"Crossref","is-referenced-by-count":22,"title":["Prevalence of Markers of Heart Failure in Patients with Atrial Fibrillation and the Effects of Ximelagatran Compared to Warfarin on the Incidence of Morbid and Fatal Events: A Report from the SPORTIF III and V Trials"],"prefix":"10.1093","volume":"9","author":[{"given":"John G.F.","family":"Cleland","sequence":"first","affiliation":[{"name":"Department of Cardiology , Kingston-upon-Hull ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiddian","family":"Shelton","sequence":"additional","affiliation":[{"name":"Department of Cardiology , Kingston-upon-Hull ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Nikitin","sequence":"additional","affiliation":[{"name":"Department of Cardiology , Kingston-upon-Hull ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Cardiology , Kingston-upon-Hull ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Frison","sequence":"additional","affiliation":[{"name":"AstraZeneca , M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretha","family":"Grind","sequence":"additional","affiliation":[{"name":"AstraZeneca , M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,5,11]]},"reference":[{"key":"2026020203481700600_ejhf2007-01-013-bib-0001","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1053\/euhj.1999.1767","article-title":"Systematic review of the management of atrial fibrillation in patients with heart failure","volume":"21","author":"Khand","year":"2000","journal-title":"Eur Heart J"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0002","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/01.CIR.101.17.2118","article-title":"Defining diastolic heart failure: a call for standardized diagnostic criteria","volume":"101","author":"Vasan","year":"2000","journal-title":"Circulation"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0003","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/euhj.1998.1057","article-title":"How to diagnose diastolic heart failure","volume":"19","author":"European Study Group on Diastolic Heart Failure","year":"1998","journal-title":"Eur Heart J"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0004","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1388-9842(03)00052-7","article-title":"Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) programme","volume":"5","author":"McMurray","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0005","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ahj.2004.09.038","article-title":"Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study","volume":"149","author":"Curtis","year":"2005","journal-title":"Am Heart J"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0006","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/eurheartj\/ehi166","article-title":"Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0007","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ahj.2004.11.015","article-title":"Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study","volume":"149","author":"DiMarco","year":"2005","journal-title":"Am Heart J"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0008","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ahj.2003.11.007","article-title":"Are hematinic deficiencies the cause of anemia in chronic heart failure?","volume":"147","author":"Witte","year":"2004","journal-title":"Am Heart J"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0009","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0010","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-8703(03)00325-9","article-title":"Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)","volume":"146","author":"Halperin","year":"2003","journal-title":"Am Heart J"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0011","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0012","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000091265","article-title":"Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies","volume":"21","author":"Diener","year":"2006","journal-title":"Cerebrovasc Dis"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0013","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1023\/A:1020097728178","article-title":"Prevention of and medical therapy for atrial arrhythmias in heart failure","volume":"7","author":"Khand","year":"2002","journal-title":"Heart Fail Rev"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0014","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0015","first-page":"1424","article-title":"Does heart failure confer a hypercoagulable state? Virchow's triad revisited","volume":"33","author":"Lip","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0016","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00001573-199705000-00009","article-title":"Anticoagulant and antiplatelet therapy in heart failure","volume":"12","author":"Cleland","year":"1997","journal-title":"Curr Opin Cardiol"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1388-9842(99)00009-4","article-title":"Sudden death in heart failure: vascular or electrical?","volume":"1","author":"Cleland","year":"1999","journal-title":"Eur J Heart Fail"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0018","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/01.CIR.0000084543.79097.34","article-title":"Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure","volume":"108","author":"Horwich","year":"2003","journal-title":"Circulation"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0019","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.amjmed.2005.02.010","article-title":"Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction","volume":"118","author":"Orn","year":"2005","journal-title":"Am J Med"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/01.CIR.102.6.611","article-title":"Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial","volume":"102","author":"Uretsky","year":"2000","journal-title":"Circulation"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0021","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"issue":"19","key":"2026020203481700600_ejhf2007-01-013-bib-0022","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/eurheartj\/ehl233","article-title":"The diagnostic utility of N-Terminal pro-B-type Natriuretic for the detection of major strucural heart desease in patients with atrial fibrillation","volume":"27","author":"Shelton","year":"2006","journal-title":"Eur Heart J"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0023","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.100.12.1311","article-title":"Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction","volume":"100","author":"Cooper","year":"1999","journal-title":"Circulation"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0024","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejheart.2004.04.014","article-title":"Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure","volume":"6","author":"Cleland","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The Warfarin\/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0026","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/pcad.2002.31597","article-title":"Is aspirin \u201cthe weakest link\u201d in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease","volume":"44","author":"Cleland","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"2026020203481700600_ejhf2007-01-013-bib-0027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/hrt.74.3.215","article-title":"Is aspirin safe for patients with heart failure?","volume":"74","author":"Cleland","year":"1995","journal-title":"Br Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2007.01.013","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/9\/6-7\/730\/66616087\/eurjhf_9_6-7_730.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/9\/6-7\/730\/66616087\/eurjhf_9_6-7_730.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:48:27Z","timestamp":1770022107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/9\/6-7\/730\/8443774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,11]]},"references-count":27,"journal-issue":{"issue":"6-7","published-online":{"date-parts":[[2007,5,11]]},"published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2007.01.013","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,6]]},"published":{"date-parts":[[2007,5,11]]}}}